tetano
Editor, Senior Moderator
Pharm Res. 2016 Jan 27. [Epub ahead of print]
[h=1]Stabilization of Live Attenuated Influenza Vaccines by Freeze Drying, Spray Drying, and Foam Drying.[/h] Lovalenti PM[SUP]1[/SUP], Anderl J[SUP]1[/SUP], Yee L[SUP]1[/SUP], Nguyen V[SUP]1[/SUP], Ghavami B[SUP]1[/SUP], Ohtake S[SUP]1[/SUP], Saxena A[SUP]1[/SUP], Voss T[SUP]2[/SUP], Truong-Le V[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]PURPOSE:[/h] The goal of this research is to develop stable formulations for live attenuated influenza vaccines (LAIV) by employing the drying methods freeze drying, spray drying, and foam drying.
[h=4]METHODS:[/h] Formulated live attenuated Type-A H1N1 and B-strain influenza vaccines with a variety of excipient combinations were dried using one of the three drying methods. Process and storage stability at 4, 25 and 37?C of the LAIV in these formulations was monitored using a TCID[SUB]50[/SUB] potency assay. Their immunogenicity was also evaluated in a ferret model.
[h=4]RESULTS:[/h] The thermal stability of H1N1 vaccine was significantly enhanced through application of unique formulation combinations and drying processes. Foam dried formulations were as much as an order of magnitude more stable than either spray dried or freeze dried formulations, while exhibiting low process loss and full retention of immunogenicity. Based on long-term stability data, foam dried formulations exhibited a shelf life at 4, 25 and 37?C of >2, 1.5 years and 4.5 months, respectively. Foam dried LAIV Type-B manufactured using the same formulation and process parameters as H1N1 were imparted with a similar level of stability.
[h=4]CONCLUSION:[/h] Foam drying processing methods with appropriate selection of formulation components can produce an order of magnitude improvement in LAIV stability over other drying methods.
[h=4]KEYWORDS:[/h] Attenuated; Drying; Influenza; Stability; Vaccine
PMID: 26818839 [PubMed - as supplied by publisher]
[h=1]Stabilization of Live Attenuated Influenza Vaccines by Freeze Drying, Spray Drying, and Foam Drying.[/h] Lovalenti PM[SUP]1[/SUP], Anderl J[SUP]1[/SUP], Yee L[SUP]1[/SUP], Nguyen V[SUP]1[/SUP], Ghavami B[SUP]1[/SUP], Ohtake S[SUP]1[/SUP], Saxena A[SUP]1[/SUP], Voss T[SUP]2[/SUP], Truong-Le V[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]PURPOSE:[/h] The goal of this research is to develop stable formulations for live attenuated influenza vaccines (LAIV) by employing the drying methods freeze drying, spray drying, and foam drying.
[h=4]METHODS:[/h] Formulated live attenuated Type-A H1N1 and B-strain influenza vaccines with a variety of excipient combinations were dried using one of the three drying methods. Process and storage stability at 4, 25 and 37?C of the LAIV in these formulations was monitored using a TCID[SUB]50[/SUB] potency assay. Their immunogenicity was also evaluated in a ferret model.
[h=4]RESULTS:[/h] The thermal stability of H1N1 vaccine was significantly enhanced through application of unique formulation combinations and drying processes. Foam dried formulations were as much as an order of magnitude more stable than either spray dried or freeze dried formulations, while exhibiting low process loss and full retention of immunogenicity. Based on long-term stability data, foam dried formulations exhibited a shelf life at 4, 25 and 37?C of >2, 1.5 years and 4.5 months, respectively. Foam dried LAIV Type-B manufactured using the same formulation and process parameters as H1N1 were imparted with a similar level of stability.
[h=4]CONCLUSION:[/h] Foam drying processing methods with appropriate selection of formulation components can produce an order of magnitude improvement in LAIV stability over other drying methods.
[h=4]KEYWORDS:[/h] Attenuated; Drying; Influenza; Stability; Vaccine
PMID: 26818839 [PubMed - as supplied by publisher]